36
Views
1
CrossRef citations to date
0
Altmetric
Review

Diagnostic markers for hepatitis virus infection

, MD & , MD
Pages 303-314 | Published online: 11 Mar 2008

Bibliography

  • Pawlotsky J-M. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122:1554-68
  • Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998;47(RRr-19):1-39
  • Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14
  • Kwiatkowski CF, Fortuin CK, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002;97:1289-94
  • Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71
  • Swain MG, Lai M-Y, Shiffman ML, et al. Sustained virological response (SVR) resulting from treatment with peginterferon alfa-2a (40KD) (Pegasys) alone or in combination with ribavirin (Copegus) is durable and constitutes a cure: an ongoing 5-year follow-up. Gastroenterology 2007;132(Suppl 2):A741
  • Zeuzem S, Fried MW, Reddy K, et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (Copegus). Hepatology 2006;44(Suppl 1):267A
  • Roque-Afonso A, Ducoulombier D, Di Liberto G, et al. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005;79:6349-57
  • Zehender G, De Maddalena C, Bernini F, et al. Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J Virol 2005;79:9145-56
  • Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: Evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000;181:442-8
  • Glenn JS. Molecular virology of the hepatitis C virus: implication for novel therapies. Clin Liver Dis 2005;9:353-69
  • Gretch D, Lee W, Corey L. Use of aminotransferase, hepatitisC antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in diagnostic virology laboratory. J Clin Microbiol 1992;30:2145-9
  • Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997;26(Suppl 1):43S-47S
  • Lok AS, Chien D, Choo Q, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993;18:497-502
  • Pawlotsky J. Diagnostic tests for hepatitis C. J Hepatol 1999;31(S1):71-9
  • Kao J, Lai M, Hwang Y, et al. Chronic hepatitis C without anti-hepatitis antibodies by second-generation assay: a clinicopathologic study and demonstration of the usefulness of a third generation assay. Dig Dis Sci 1996;41:161-5
  • Ferreura-Gonzalez A, Shiffman ML. Use of Diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis 2004;24(2):9-18
  • Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007;356:1445-54
  • Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR 2003;52(RR-3):1-16
  • Klimashevskaya S, Obriadina A, Ulanova T, et al. Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index. J Clin Microbiol 2007;45:3400-3
  • Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007;40:110-5
  • Seme K, Poljak M, Babic DZ, et al. The role of core antigen detection in management of hepatitis C: a critical review. J Clin Virol 2005;32:92-101
  • Saldanha J, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang 1999;76:149-58
  • Pawlotsky J, Bouvier-Alias M, Hezode C, et al. Standardization of hepatitis C virus RNA quantification. Hepatology 2000;32:654-9
  • Chalker VJ, Rossouw A, Mee Z, et al. External quality assessment for the molecular detection of hepatitis C virus. J Clin Virol 2007;39:141-4
  • Krajden M, Ziermann R, Khan A, et al. Qualitative detection of hepatitis C virus RNA: Comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol 2002;40:2903-7
  • Desombere I, Vlierberghe HV, Couvent S, et al. Comparison of qualitative (Cobas Amplicor HCV 2.0 versus Versant HCV RNA) and quantitative (Cobas Amplicor HCV Monitor 2.0 versus Versant HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. J Clin Microbiol 2005;43:2590-7
  • Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky J. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007;46:22-31
  • Morishima C, Morgan TR, Everhart JE, et al. HCV RNA detection by TMA during hepatitis C anti-viral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006;44:360-7
  • Chevaliez S, Pawlotsky J. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci 2006;3:35-40
  • Podzorsi RP. Molecular testing in the diagnosis and management of hepatitis C virus infection. Arch Pathol Lab Med 2002;126:285-90
  • Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007;297:724-32
  • Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45
  • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107
  • Shepard CW, Simard EP, Finelli AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006;28:112-25
  • Center for disease control and prevention. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Part 1. Immunization of Infants, Children, and Adolescents. MMWR 2005;54(RR16):1-23
  • Harrison TJ. Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 2006;26:87-96
  • Bowden S. Serological and molecular diagnosis. Semin Liver Dis 2006;26:97-103
  • Weber B. Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene. Expert Rev Mol Diagn 2005;5:75-91
  • Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39
  • Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular cancinoma across a biological gradient of serum hepatitis B DNA level. JAMA 2006;295:65-73
  • Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
  • Hoofnagle JU, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-75
  • Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology 2007;32:1586-94
  • Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-65
  • Palumbo E. Hepatiits B genotypes and response to antiviral therapy: a review. Am J Ther 2007;14:306-9
  • Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev 2007;20:426-39
  • Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut54:1009-13
  • Kao J, Chen D. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403
  • Zaaijer HL, Vrielink H, Koot M. Early detection of hepatitis B surface antigen and detection of HBsAg mutants: a comparison of five assays. Vox Sang 2001;81:219-21
  • Chen D, Kaplan LA. Performance of a new-generation chemiluminescent assay for hepatitis B surface antigen. Clin Chem 2006;82:1592-8
  • Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005;24:786-92
  • Werle-Laposstolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8
  • Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98
  • Welzel TM, Miley WJ, et al. Real time PCR assay for detection and quantification of hepatitis B virus genotypes A to G. J Clin Microbiol 2006;44:3325-33
  • Saldanha J, Gerlich W, Lelie N, et al. An international collaborative study to establish a World Health Organization international standard foe hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71
  • Liu Y, Hussain M, Wong S, et al. A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol 2007;45:553-8
  • Zanetti AR, Romano L, Zappa A, Velati C. Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. J Clin Virol 2006;36(Suppl 1):S51-5
  • Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diagn Ther 2006;10:77-91
  • Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006;91:1-12
  • Hussain M, Chu C, Sablon E, Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003;41:3699-705
  • Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7
  • Hadler SC, Webster HM, Erben JJ, et al. Hepatitis A in day-care centers. A community-wide assessment. N Engl J Med 1980;302:1222-7
  • Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985;122:226-33
  • Wise ME, Sorvillo F. Hepatitis A-related mortality in California, 1989–2000: analysis of multiple cause-coded death data. Am J Public Health 2005;95:900-5
  • Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005;294:194-201
  • Nainan OV, Xia G, Vaughan G, Margolis HS. Diagnosis of hepatitis A virus infection: a molecular approach. Clin Microbiol Rev 2006;19:63-79
  • Eble K, Clemens J, Krenc C, et al. Differential diagnosis of acute viral hepatitis using rapid, fully automated immunoassays. J Med Virol 1991;22:139-50
  • Wiedmann M, Boehm S, Schumacher W, et al. Evaluation of three commercial assays for the detection of hepatitis A virus. Eur J Clin Microbiol Infect Dis 2003;22:129-30
  • Roque-Afonso A, Grangeot-Keros L, Roquebert, et al. Diagnostic relevance of immunoglobulin G avidity for hepatitis A virus. J Clin Microbiol 2004;42:5121-4
  • Farci P. Delta hepatitis: an update. J Hepatol 2003;39:S212-9
  • Aragona M, Macagno S, Caredda F, et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet 1987;28:478-80
  • Bezeaud A, Rosenswajg, Guillin MC. Evaluation of five hepatitis delta virus marker assays for detection of antigen and antibody. J Clin Microbiol 1989;27:2880
  • Growans EJ, Macnaughton TB, Mickan L, et al. Use of recombinant hepatitis delta antigen in diagnostic assays for HDV antibody. J Virol methods 1990;27:69-78
  • Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003;43:721-9
  • Pillonel J, Laperche S, et al. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005;10:5-8
  • Zoulim F. New nucleic acid diagnostic tests in viral hepatitis. Semin Liver Dis 2006;26:309-17
  • Wiedmann M, Kluwick S, Walter M, et al. HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas TaqScreen MPX test in seroconverting donors. J Clin Virol 2007;39:282-7
  • Acharya SK, Panda SK. Hepatitis E virus: epidemiology, diagnosis, pathology and prevention. Trop Gastroenterol 2006;27:63-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.